Masafumi Ikeda

机构：National Cancer Center Hospital East · ORCID：0000-0002-4050-2086

发表论文 1017 篇 · 总被引 35808 次 · h-index 80

代表论文

• Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial (2025 · Journal of Clinical Oncology · 被引 26)
• Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers (2025 · Liver International · 被引 10)
• Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations (2025 · Clinical Cancer Research · 被引 7)
• E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma (2025 · Clinical Cancer Research · 被引 7)
• Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab (2025 · European Journal of Cancer · 被引 3)
• Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis (2025 · Liver Cancer · 被引 1)